Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 4/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016780 | 0.78 | LMNA (0.33) | LMNAADORA3KDM5BBRD4 | |
| SCHEMBL21479571 | 0.71 | — | — | |
| SCHEMBL26714027 | 0.71 | LMNA (0.32) | LMNAADORA3 | |
| SCHEMBL26714122 | 0.69 | — | — | |
| SCHEMBL24869043 | 0.67 | CREBBP (0.43) | CREBBPBRD4 | |
| SCHEMBL18644923 | 0.65 | FAAH (0.33) | LMNAADORA3BRD4TLR9TLR8 | |
| SCHEMBL21479559 | 0.65 | — | — | |
| SCHEMBL20844030 | 0.65 | — | — | |
| SCHEMBL18651544 | 0.64 | LMNA (0.41) | LMNAADORA3KDM5BCREBBPBRD4 | |
| SCHEMBL22623683 | 0.63 | BRD4 (0.43) | LMNAADORA3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | LMNA 2900/4885ADORA3 1752/4885KDM5B 1244/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | LMNA 2900/4885ADORA3 1752/4885KDM5B 1244/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | LMNA 2991/4885ADORA3 1388/4885KDM5B 903/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | LMNA 2900/4885ADORA3 1752/4885KDM5B 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.